Active — Not RecruitingPhase 2

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

Canada20 participantsStarted 2025-06-05

Plain-language summary

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

Who can participate

Age range50 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted Exclusion Criteria: * Pre-existing heart failure and pulmonary artery hypertension. * Known thrombocytopenia. * Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic. * Known sensitivity to prostanoids * Severe hepatic insufficiency

What they're measuring

Exercise tolerance

Timeframe: Within 30-45 minutes post dose

Exertional dyspnea

Timeframe: Within 30-45 minutes post dose

Ventilatory efficiency

Timeframe: Within 30-45 minutes post dose

Trial details

NCT IDNCT06969573

SponsorUniversity of Alberta

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More COPD (Chronic Obstructive Pulmonary Disease) trials